PL1697394T3 - Inhibitory COMT - Google Patents
Inhibitory COMTInfo
- Publication number
- PL1697394T3 PL1697394T3 PL04803816T PL04803816T PL1697394T3 PL 1697394 T3 PL1697394 T3 PL 1697394T3 PL 04803816 T PL04803816 T PL 04803816T PL 04803816 T PL04803816 T PL 04803816T PL 1697394 T3 PL1697394 T3 PL 1697394T3
- Authority
- PL
- Poland
- Prior art keywords
- comt
- sup
- diseases
- compounds
- treatment
- Prior art date
Links
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 abstract 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104828 | 2003-12-19 | ||
| PCT/EP2004/014186 WO2005058228A2 (en) | 2003-12-19 | 2004-12-13 | Comt inhibitors |
| EP04803816A EP1697394B1 (en) | 2003-12-19 | 2004-12-13 | Comt inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1697394T3 true PL1697394T3 (pl) | 2007-08-31 |
Family
ID=34673618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04803816T PL1697394T3 (pl) | 2003-12-19 | 2004-12-13 | Inhibitory COMT |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7319101B2 (pl) |
| EP (1) | EP1697394B1 (pl) |
| JP (1) | JP2007514677A (pl) |
| KR (1) | KR100814737B1 (pl) |
| CN (1) | CN100447149C (pl) |
| AT (1) | ATE357453T1 (pl) |
| AU (1) | AU2004298343B2 (pl) |
| BR (1) | BRPI0417799A (pl) |
| CA (1) | CA2548300A1 (pl) |
| DE (1) | DE602004005502T2 (pl) |
| ES (1) | ES2282924T3 (pl) |
| MX (1) | MXPA06005894A (pl) |
| PL (1) | PL1697394T3 (pl) |
| RU (1) | RU2354655C2 (pl) |
| WO (1) | WO2005058228A2 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| FR2893617A1 (fr) * | 2005-11-24 | 2007-05-25 | Inst Nat Sante Rech Med | Analogues photoactivables du nadh, du nadph, du nad+ ou du nadp+ |
| WO2007063789A1 (ja) * | 2005-11-29 | 2007-06-07 | Kissei Pharmaceutical Co., Ltd. | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20090012177A1 (en) * | 2006-03-23 | 2009-01-08 | Rahim Shafa | Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs |
| CN103391939B (zh) * | 2010-12-03 | 2016-03-09 | Epizyme股份有限公司 | 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物 |
| TWI638802B (zh) | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚ｏ－甲基轉移酶活性抑制化合物 |
| EP2938600B1 (en) | 2012-12-27 | 2017-01-25 | F. Hoffmann-La Roche AG | Comt inhibitors |
| WO2014152566A2 (en) | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| CN105218377B (zh) * | 2015-09-14 | 2017-10-27 | 西安交通大学 | 一种羟基酪醇no供体衍生物及其制备方法和应用 |
| CN107935953A (zh) * | 2017-12-31 | 2018-04-20 | 佛山市赛维斯医药科技有限公司 | 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途 |
| CN108218796A (zh) * | 2017-12-31 | 2018-06-29 | 佛山市赛维斯医药科技有限公司 | 含酰肼结构的化合物、制备方法及其用途 |
| CN108129406A (zh) * | 2017-12-31 | 2018-06-08 | 佛山市赛维斯医药科技有限公司 | 一种含末端烯键和酰肼结构的comt抑制剂及其用途 |
| CN108191783A (zh) * | 2017-12-31 | 2018-06-22 | 佛山市赛维斯医药科技有限公司 | 一类苯甲胺三嗪结构的comt抑制剂、制备方法及其用途 |
| CN107987026A (zh) * | 2017-12-31 | 2018-05-04 | 佛山市赛维斯医药科技有限公司 | 末端烯丙基的丙酰肼嘧啶结构的化合物、制备方法及其用途 |
| CN107973758A (zh) * | 2017-12-31 | 2018-05-01 | 佛山市赛维斯医药科技有限公司 | 一类三嗪和酰肼结构的comt抑制剂、制备方法及其用途 |
| CN107903216A (zh) * | 2017-12-31 | 2018-04-13 | 佛山市赛维斯医药科技有限公司 | 一种含丙酰肼和嘧啶结构的化合物及其用途 |
| CN108148004A (zh) * | 2017-12-31 | 2018-06-12 | 佛山市赛维斯医药科技有限公司 | 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途 |
| CN107987025A (zh) * | 2017-12-31 | 2018-05-04 | 佛山市赛维斯医药科技有限公司 | 一类含丙酰肼结构的化合物、制备方法及其用途 |
| CN108191775A (zh) * | 2017-12-31 | 2018-06-22 | 佛山市赛维斯医药科技有限公司 | 一种末端烯丙基丙酰肼结构化合物及其用途 |
| CN108148010A (zh) * | 2017-12-31 | 2018-06-12 | 佛山市赛维斯医药科技有限公司 | 含酰肼结构的comt抑制剂、制备方法及其用途 |
| CN117720405A (zh) * | 2023-11-20 | 2024-03-19 | 长沙创新药物工业技术研究院有限公司 | 一种1-[3-氯-5-(三氟甲基)苯基]-2,2,2-三氟乙酮的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| GB2238047B (en) * | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
-
2004
- 2004-12-13 WO PCT/EP2004/014186 patent/WO2005058228A2/en not_active Ceased
- 2004-12-13 CA CA002548300A patent/CA2548300A1/en not_active Abandoned
- 2004-12-13 MX MXPA06005894A patent/MXPA06005894A/es active IP Right Grant
- 2004-12-13 JP JP2006544301A patent/JP2007514677A/ja active Pending
- 2004-12-13 AU AU2004298343A patent/AU2004298343B2/en not_active Ceased
- 2004-12-13 CN CNB2004800353050A patent/CN100447149C/zh not_active Expired - Fee Related
- 2004-12-13 PL PL04803816T patent/PL1697394T3/pl unknown
- 2004-12-13 ES ES04803816T patent/ES2282924T3/es not_active Expired - Lifetime
- 2004-12-13 DE DE602004005502T patent/DE602004005502T2/de not_active Expired - Lifetime
- 2004-12-13 EP EP04803816A patent/EP1697394B1/en not_active Expired - Lifetime
- 2004-12-13 AT AT04803816T patent/ATE357453T1/de active
- 2004-12-13 RU RU2006125748/04A patent/RU2354655C2/ru not_active IP Right Cessation
- 2004-12-13 BR BRPI0417799-1A patent/BRPI0417799A/pt not_active IP Right Cessation
- 2004-12-13 KR KR1020067012029A patent/KR100814737B1/ko not_active Expired - Fee Related
- 2004-12-14 US US11/011,887 patent/US7319101B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100447149C (zh) | 2008-12-31 |
| US20050137162A1 (en) | 2005-06-23 |
| AU2004298343A1 (en) | 2005-06-30 |
| RU2354655C2 (ru) | 2009-05-10 |
| BRPI0417799A (pt) | 2007-04-17 |
| US7319101B2 (en) | 2008-01-15 |
| DE602004005502D1 (de) | 2007-05-03 |
| RU2006125748A (ru) | 2008-01-27 |
| CA2548300A1 (en) | 2005-06-30 |
| WO2005058228A2 (en) | 2005-06-30 |
| WO2005058228A3 (en) | 2005-12-08 |
| JP2007514677A (ja) | 2007-06-07 |
| MXPA06005894A (es) | 2006-06-27 |
| KR20060103266A (ko) | 2006-09-28 |
| KR100814737B1 (ko) | 2008-03-19 |
| EP1697394A2 (en) | 2006-09-06 |
| ES2282924T3 (es) | 2007-10-16 |
| DE602004005502T2 (de) | 2007-11-29 |
| ATE357453T1 (de) | 2007-04-15 |
| AU2004298343B2 (en) | 2010-05-27 |
| EP1697394B1 (en) | 2007-03-21 |
| CN1886416A (zh) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE357453T1 (de) | Comt-inhibitoren | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
| IL179634A0 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitor | |
| SE0202462D0 (sv) | Novel use | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| MXPA05011207A (es) | Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo). | |
| MXPA04010055A (es) | Derivados de tioxantina como inhibidores de mieloperoxidasa. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| WO2001078711A3 (en) | Pde-v inhibitors for treatment of parkinson's disease | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| ZA200501098B (en) | Novel use of benzothiazole derivatives | |
| JO2282B1 (en) | Oxazole derivatives | |
| AU2003266330A1 (en) | Hetereoaryl nitrile derivatives | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| PT1696905E (pt) | 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson | |
| ZA200705018B (en) | Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease | |
| MY133527A (en) | Isoquinoline derivatives | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| WO2003070728A3 (en) | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders | |
| SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
| IL178167A0 (en) | 1,3,4-oxadiazol-2-ones as ppar delta modulators | |
| SE0402591D0 (sv) | Novel use |